Pharma stocks face Q4 reality check amid global headwinds

Analysts expect modest revenue growth but pressure on profitability in the March quarter

Dabur reports steady domestic growth amid global headwinds in Q4 FY26

The India FMCG business showed a sequential recovery and is expected to post high-single digit growth

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results

Hikal swings back to profit in Q4 FY26 despite regulatory hit & strategic charges

Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments

Gandhar Oil posts robust FY26 profit

PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion

Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure

Solara's strong Q4 lifts FY26 finish but ibuprofen drag forces strategic review

The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million

Akums posts strong FY26 performance as EBITDA surges 61.6% in Q4

Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook

Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros

Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth

The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion